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The effect of sequential high-dose intravenous strep- 
tokinase (SK) (1.5 million units) followed by emer- 
gency percutaneous transluminal coronary angio- 
plasty (PTCA) on preserving left ventricular function 
was assessed prospectively in 34 patients with 
acute myocardial infarction (AMI). Intravenous SK 
therapy was initiated 2.6 f 1.3 hours (mean f 
standard deviation) after the onset of chest pain. 
Urgent coronary angiography showed perslstent to- 
tal occlusion in 13 patients, significant diameter ste- 
nosis (70 to 99 % ) in 16 patients and a widely pat- 
ent artery (less than 50% stenosis) in 3 patients. 
Emergency PTCA was performed in 29 patients 5.0 
f 2.1 hours after symptom onset. Successful re- 
canalization was achieved in 33 of the 34 patients 
(97 % ) treated with sequential therapy. Repeat 
contrast ventriculograms recorded 7 to 10 days af- 
ter intervention in 23 patients showed that the left 
ventricular ejection fraction increased from 53 f 
12% to 59 f 13 % (area-length method, p 
<0.002). Regional wall motion of the infarcted seg- 
ments improved from -2.7 f 1.1 to -1.5 f 1.7 
SD/chord (centerline method, p <0.003). In the 
subgroup of patients with an occluded artery on ini- 
tial angiography (group A, n = IO), both global lefl 
ventricular ejection fraction (49 f 12% vs 59 f 
12%, p <0.002) and regional wall motion (-3.2 f 
1.0 vs -1.9 f 1.7 SD/chord, p <0.002) improved 
significantly. In contrast, no significant improvement 
was seen in patients with a patent artery on initial 
angiography (n = 13). Thus, sequential intravenous 
SK and emergency PTCA is efficacious in achieving 
coronary reperfusion and in improving both global 
and regional left ventricular function. When throm- 
bolytic therapy fails, successful recanalization can 
be achieved by emergency PTCA, resulting in sig- 
nificant myocardial salvage. 
(Am J Cardiol 1966;56:666-691) 
T hrombolysis with streptokinase (SK] early after the 
onset of acute myocardial infarction (AMI) can rees- 
tablish anterograde coronary blood flow and may sal- 
vage myocardium.1 However, depending on the route 
of administration, 20 to 70% of occluded arteries 
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may not be successfully recanalized by thrombolytic 
agents.2-4 Moreover, even if thrombolysis is successful, 
significant residual stenosis usually remains at the site 
of initial occlusion5 This may restrict potential in- 
creases in coronary blood flow, act as a nidus for re- 
thrombosis and reinfarction, and lead to an unstable 
clinical course.6-8 Recently, emergency percutaneous 
transluminal coronary angioplasty (PTCA) has been 
used to recanalize acutely occluded coronary arteries. 
PTCA causes more complete revascularization, and 
initial results have been encouraging.g-ll A major 
drawback to use of PTCA alone as a treatment strategy 
is the significant interval between onset of chest pain 
to catheterization and initiation of treatment. Since 
preservation of myocardium depends in part on the 
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speed of reestablishing anterograde coronary blood 
flow, excessive delay may decrease the likelihood 
of myocardial salvage. l2 Sequential therapy using in- 
travenous SK followed by emergency PTCA is theo- 
retically attractive because this method combines 
the advantage of early intervention provided by intra- 
venous SKI3 with the more “definitive” revasculariza- 
tion provided by PTCA. When thrombolysis by SK is 
successful, earlier reperfusion is accomplished. If 
thrombolysis fails, PTCA has the potential to achieve 
recanalization. 
Since no previous clinical trial has used this com- 
bined treatment strategy, we prospectively studied 34 
patients who received sequential high-dose intrave- 
nous SK followed by emergency PTCA for the treat- 
ment of AMI. We assessed the safety and morbidity 
associated with combined therapy and obtained pilot 
data concerning the impact of such therapy on ventric- 
ular function before embarking on a large, multi- 
center, prospective randomized clinical trial of throm- 
bolysis and PTCA during AMI. 
Methods 
Patient selection: Patients with typical chest pain 
for more than 20 minutes, unrelieved by sublingual 
nitroglycerin, associated with electrocardiographic ev- 
idence of AM1 (ST elevation 2 mm or new pathologic 
Q waves in 2 or more leads) were considered eligible 
for this study. Symptom onset of less than 6 hours was 
required before initiation of intravenous SK. Exclu- 
sion criteria were: cardiogenic shock, prior SK thera- 
py, prior coronary artery bypass surgery, bleeding 
diathesis, recent surgery, recent cerebrovascular acci- 
dent, recent cardiopulmonary resuscitation, age older 
than 75 years, pregnancy or significant hepatic disease. 
Patients gave informed consent for cardiac catheter- 
ization, thrombolysis and PTCA. 
Interventional protocol (Fig. 1): After giving in- 
formed consent, eligible patients (97%] received pre- 
medication intravenously with hydrocortisone, 200 
mg. SK, 1.5 million units, was given intravenously over 
30 minutes. Meanwhile, arrangements were made to 
transport the patient to our cardiac catheterization lab- 
oratory for emergency angiography. 
After placement of vascular sheaths, heparin, 5,000 
units, was administered intravenously. Selective coro- 
nary angiography was performed using the Judkins 
technique. This was followed by contrast ventriculog- 
raphy. Patients with at least 70% stenosis of the in- 
farct-related coronary artery were considered for 
emergency PTCA. Predefined angiographic exclusion 
criteria for PTCA were: (1) at least 60% left main ste- 
nosis: (2) “left main equivalent” lesions with at least 
70% diameter stenosis of both the proximal left anteri- 
or descending and the proximal left circumflex arte- 
ries: (3) inability to identify an infarct-related coronary 
artery; and (4) distal coronary occlusive lesions judged 
to be not amenable to PTCA. Angioplasty was per- 
formed by the Gruentzig technique14 using a steerable 
guidewire and balloon catheter system (USC1 Divi- 
sion, Bard Corp.). Additional heparin, 5,000 units, was 
given intravenously before PTCA. 
After angiography, patients were placed on a medi- 
cal regimen to prevent rethrombosis, consisting of as- 
pirin, 325 mg 3 times per day, dipyridamole, 75 mg 3 
times per day, and diltiazem, 30 mg 3 times per day. 
Heparin infusion was initiated when the serum fibrin- 
ogen level was more than 100 mg%, and therapeutic 
anticoagulation was maintained until repeat angiogra- 
phy was performed 7 to 10 days later. In addition, low- 
molecular-weight dextran, 40 ml/hour, was given in- 
travenously in the first 24 hours. 
Analysis of left ventriculograms and coronary an- 
giograms: Outlines of right anterior oblique contrast 
ventriculograms were traced manually by indepen- 
dent observers blinded to patient’s identity, coronary 
anatomy and sequence of treatment. Ejection fraction 
was calculated using an area-length method-l5 Region- 
al wall motion was measured by the computer-assisted 
centerline chord method described by Bolson et a1.16 
Wall motion abnormality was calculated as the mean 
motion of chords lying in the most hypokinetic 50% of 
the territory of the infarct artery, and expressed in 
standard deviations per chord (SD/chord). Selective 
coronary angiography was performed using multiple 
projections. The projection in which the lesion ap- 
peared most severe was chosen for analysis. Percent 
diameter stenosis was measured using handheld 
calipers. 
Statistical analysis: Values reported are mean f 
SD. Paired and nonpaired Student t tests were used 
where appropriate. Significance was at the p <0.05 
level. 
Results 
Acute intervention: During a 6-month study peri- 
od, 115 patients with AM1 were referred to our cardiac 
catheterization laboratory for acute interventional 
therapy. Of these, 34 patients fulfilled the entry criteria 
Acute Myocardial infarction 
34 Patients 
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Total Occlusion Significant Stenosis 
(100%) 
Widely Patent Vessel 
(70-99%) (<50%) 
13 Patients 18 Patients 3 Patients 
f \t 
Emergency PTCA Emergency PTCA No PTCA 
t c 
5 Patients 
Success 12/13 Success 16116 
FIGURE 1. Treatment scheme. PTCA = percutaneous transluminal 
coronary angiography. 
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TABLE I Clinical and Angiographic Characteristics 
Group A- Group S- Group C- 
Total 70-99 % <50% 
Occlusion Stenosis Stenosis 
Sex ratio (male:female) 
Time from symptom onset 
to SK (hours) 
Time from symptom onset 
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13 18 
58f 12 55f 13 
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2.6 f 1.2 2.6 f 1.5 
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LAD = left anterior descending coronary artery; LC = left circumflex artery: 
PTCA = percutaneous transluminal coronary angioplasty; SK = streptokinase. 
and received intravenous SK (1.5 million units] before 
arrival in our laboratory. The remaining patients did 
not receive thrombolytic therapy before transfer either 
because they failed to meet the entry criteria or be- 
cause use of intravenous SK had not been approved by 
the outlying community hospital. They were treated 
with emergency PTCA if possible. All 34 patients who 
received intravenous SK had elevated creatine ki- 
nase-MB isoenzyme values documenting the pres- 
ence of AMI. SK therapy was initiated 2.6 f 1.3 hours 
(range 1 to 6) after the onset of chest pain. Systemic 
lytic state was achieved in all patients with serum fi- 
brinogen levels of less than 60 mg% (range <15 to 54 
mg%) and fibrin split product detectable at more than 
l/128 dilution (range l/128 to l/1024). 
At initial angiography, the infarct-related coronary 
artery was occluded in 13 patients (group A], signifi- 
cantly narrowed (70 to 99% stenosis) in 18 (group B) 
and widely patent (less than 50% stenosis] in 3 (group 
C). Five of these 34 patients were excluded from PTCA 
based on predefined criteria mentioned in the Meth- 
ods section. Three patients had a widely patent vessel 
(group C], 1 patient had subtotal occlusion of a distal 
vessel judged to be not amenable to PTCA (group B), 
and 1 had an inferior infarct with 3-vessel coronary 
disease in whom an infarct-related vessel could not be 
identified (group B). 
PTCA was attempted in the other 13 group A and 16 
group B patients 2.4 f 1.3 hours (range 1 to 6) after SK 
infusion. Mechanical dilatation was successful in 28 
patients decreasing the luminal diameter narrowing 
by at least 20%. The only failure was in a patient with a 
totally occluded left anterior descending artery in 
whom PTCA attempt resulted in dissection, That pa- 
tient’s subsequent clinical course was stable. After 
successful reperfusion with sequential therapy, only 2 
patients had residual stenosis of the infarct-related 
artery of at least 70%. The clinical characteristics and 
the angiographic data of the 3 groups of patients are 
summarized in Table I. 
Complications: In 6 patients significant hypoten- 
sion developed during SK infusion, The patients im- 
proved after intravenous fluid and slowing of the SK 
infusion. One patient with anterior infarction became 
hypotensive after completion of SK therapy and be- 
fore cardiac catheterization, Angiography showed 
multivessel disease with complete left anterior de- 
scending artery occlusion. That patient died from car- 
diogenic shock despite recanalization by PTCA. Re- 
perfusion arrhythmia occurred in 9 patients. Sustained 
ventricular tachycardia or fibrillation occurred in 2 
patients, and carioversion was successful in both. Both 
patients had nonsustained ventricular tachycardia. 
One patient had transient complete heart block during 
SK infusion. Bleeding complications occurred in 12 
patients, hematoma at the access site in 7, gastrointesti- 
nal bleeding in 3, hematuria in 1 patient and hemopty- 
sis in 1. Three patients required at least 2 units of blood 
transfusion, representing significant morbidity. In 1 
patient cardiogenic shock developed soon after initial 
angiography. Total occlusion of the left anterior de- 
scending artery was documented on angiography. Re- 
canalization was achieved with PTCA; however, the 
patient died from pump failure soon after the proce- 
dure. Coronary reocclusion was documented in z-of 26 
patients who had repeat cardiac catheterization. Reoc- 
elusion was silent in 1 patient and in the other, chest 
pain developed that was associated with further ST- 
segment elevation 24 hours after successful PTCA. Re- 
peat angiography showed reocclusion and repeat 
PTCA was successful. 
Global ventricular function assessment: Contrast 
ventriculograms recorded soon after admission (early) 
were compared with those recorded 7 to 10 days later 
(late]. Of the 13 group A patients with an occluded 
artery on the initial angiogram, 10 had satisfactory seri- 
al ventriculograms for analysis. The late ventriculo- 
gram was technically inadequate for analysis in 1 pa- 
tient, and 2 patients died. Left ventricular ejection 
fraction improved from 49 f 12% to 59 f 12% (n = 10, 
p CO.002) (Fig. 2). In 1 patient reperfusion was not 
achieved because of coronary dissection during 
PTCA, and 1 patient had reocclusion. Seven of the 
remaining 8 patients with persistently recanalized ves- 
sels had at least a 5% increase in ejection fraction. Of 
the 18 group B patients with a significantly stenosed 
artery on initial angiography, 13 had satisfactory serial 
contrast ventriculograms for analysis. Two patients did 
not undergo PTCA and 2 with an uncomplicated clini- 
cal course refused follow-up studies. In 1 patient, the 
late ventriculogram was technically of poor quality 
unsuitable for analysis. Left ventricular ejection frac- 
tion was 56 f 10% on the initial angiogram and 59 f 
10% at follow-up (n = 13, p = 0.19) (Fig. 21. One patient 
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had symptomatic reocclusion. Six of the remaining 12 
patients had at least a 5% increase in ejection fraction. 
Five of these 6 patients had at least 90% stenosis of the 
infarct-related artery on initial angiography. Of the 3 
group C patients with a widely patent artery on the 
initial angiogram, serial ventriculograms were avail- 
able only in 1 patient. Ejection fraction improved from 
47% to 54%. The other 2 patients had no discernible 
coronary lesions on the initial angiogram, and follow- 
up studies were not performed. 
When all the group A and B patients with satisfacto- 
ry serial ventriculograms were analyzed (n = 23), ejec- 
tion fraction improved from 53 f 12% to 59 f 13% (p 
<O.O02). Intergroup comparisons between group A and 
group B showed a significantly greater increase of 
mean ejection fraction for group A (9.9 f 6.7% vs 3.0 f 
7.5%, p <O.O4). The early ejection fraction in group A 
tended to be lower, but the difference was not signifi- 
cant (49 f 12% vs 56 f 109’0, p = 0.18). The late ejection 
fraction of the 2 groups were nearly identical (59 f 
12% vs 59 f 1070, p = 0.98). 
Regional ventricular function assessment: Group 
A patients achieved significant improvement of re- 
gional ventricular function of the infarcted segments 
(-3.2 f 1.0 vs -1.9 f 1.7 SD/chord, p <0.002, n = lo), 
while group B patients did not (-2.2 f 1.0 vs -1.2 f 1.8 
SD/chord, p = 0.06, n = 13). Results are summarized in 
Figure 3. Among patients with persistently recanalized 
vessels, 6 of the 8 patients in group A and 5 of the 12 in 
group B had improvement of at least 1 SD/chord. 
When all group A and group B patients with satis- 
factory ventriculograms were analyzed, regional ven- 
tricular function of the infarcted segments improved 
from -2.7 f 1.1 to -1.5 f 1.7 SD/chord (p <0.003, n = 
231, while regional function of the noninfarcted seg- 
ments did not change (1.2 f 1.5 vs 1.0 f 1.6 SD/chord, 
p = 0.55, n = 23). Intergroup comparisons between 
group A and group B did not yield a significant differ- 
ence in the degree of regional wall motion improve- 
ment (1.3 f 1.2 vs 1.0 f 1.8, SD/chord, p = 0.67). Re- 
gional wall motion of the infarcted segments was less 
hypokinetic in group B patients than in group A pa- 
tients on early ventriculograms (-2.2 f 1.0 SD/chord 













FIGURE 2. Left ventricular ejection fraction (LVEF) on initial angi- 
ography (early [El) and 10 days after therapy (late [L]) in groups A, 
I3 and C. “Follow-up ventriculogram not available. 
<O.O3), but did not show a significant difference on late 
ventriculograms (-1.2 f 1.8 SD/chord for group B vs 
-1.9 f 1.7 SD/chord for group A, p = 0.66). 
Discussion 
Intravenous SK has become an accepted treatment 
strategy for AM1 because of its rapid delivery13J7 and 
efficacy in decreasing mortality.18 However, this ther- 
apy may have major deficiencies. Irrespective of the 
route of administration, recanalization may not occur. 
In addition, thrombolytic therapy is directed only at 
the thrombotic occlusion that precipitated the acute 
event, whereas the underlying, often severely stenotic 
lesion is unaltered. Presence of these residual lesions 
may have adverse clinical sequelae, including in- 
creased incidence of reinfarction or postinfarction 
angina.lg 
PTCA has been used successfully as the primary 
method of recanalization in acute coronary occlusion. 
This is a more definitive form of therapy, permitting 
dilatation of persisting high-grade residual stenosis 
and potentially maximizing the degree of coronary re- 
perfusiong-l1 However, the time lag required to per- 
form this procedure results in prolongation of ischemia 
or injury. This problem is most apparent in many com- 
munity hospitals, where 24-hour angioplasty capabili- 
ty is not available or feasible. Combined intracoronary 
SK and PTCA has also been used successfully in many 
centers, and was found to be particularly useful when 
recanalization had failed to occur with intracoronary 
SK.gJOJOJ1 Such a combined approach, however, re- 
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FIGURE 3. Regional wall motion (RWM) of the infarcted segments 
on in/tial angiography (early [El) and 10 days after therapy (late[L]) 
in groups A and B. 
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Thromholysis: In this study, SK administration pre- 
ceded emergency PTCA by a mean of 2.5 hours. This 
time course resulted because the majority of the study 
patients received SK in the emergency rooms of outly- 
ing community hospitals, and there was some inev- 
itable time delay to transport them to the cardiac 
catheterization laboratory of our hospital. Although 
angiography was not performed before SK therapy, 
62% of the patients had a patent infarct-related coro- 
nary artery on initial angiography. This figure is higher 
than the 35% reperfusion rate reported in the Throm- 
bolysis in Myocardial Infarction trial,3 lower than the 
96% reported by Ganz et a1,17 and is similar to the 
results of Verstraete et ak4 Schroder et alz2 and Ander- 
son et a1.23 Moreover, this rate is higher than expected 
in the absence of thrombolytic therapy.24 Thus, many 
of our patients achieved early reperfusion probably as 
a result of the thrombolytic agent. As expected, most of 
the recanalized infarct-related coronary arteries had 
high-grade residual stenosis. 
Angioplasty: PTCA was successful in 28 of the 29 
patients (97%] in whom it was attempted. The success 
rate was high both in patients with occluded arteries 
and those with significant stenoses. Our results com- 
pare favorably with those reported by Papietro et akzl 
who performed PTCA after intracoronary SK admin- 
istration. As previous studies have shown,gJO the pres- 
ence of a systemic lytic state did not appear to adverse- 
ly affect the performance of PTCA in the present 
study. Reocclusion occurred in 2 of the 25 patients (8701 
who underwent immediate PTCA and repeat angiog- 
raphy despite use of heparin, dextran, aspirin, dipyrid- 
amole and a calcium blocker, suggesting that the 
thrombotic tendency of some vessels is not abolished 
by sequential therapy and aggressive medical man- 
agement. Similar results were reported by Erbel et a1.25 
Effect on ventricular function: Both regional and 
global ventricular function improved significantly af- 
ter sequential therapy, and this improvement was most 
apparent in patients who had an occluded infarct-re- 
lated vessel on the initial angiogram. This benefit may 
be related to PTCA-induced reperfusion; SK treat- 
ment alone had already failed. Previous studies by 
Rentrop et alz6 and Rogers et alz7 suggest that patients 
with incomplete occlusion of the infarct-related coro- 
nary artery may have significant improvement of ven- 
tricular function after thrombolytic therapy. In the 
current study, patients who had already achieved re- 
canalization before PTCA showed less hypokinesia of 
the infarcted segments on baseline ventriculograms 
(-2.2 f 1.0 for group B vs -3.2 f 1.0 SD/chord for 
group A, p <0.03], with a trend toward a higher base- 
line ejection fraction (56 f 10% for group B vs 49 f 
12% for group A, p = 0.181, perhaps reflecting the early 
beneficial effects of either spontaneous or SK-induced 
reperfusion. This is consistent with the observation 
that ejection reaction during the acute phase of infarc- 
tion is higher in patients with incomplete occlusions 
that permit residual anterograde flow.z8 After PTCA, 
further improvement of ventricular function was not 
shown statistically in this subgroup of patients, al- 
though a trend was suggested for global (56 f 10% vs 
59 f 1070, p = 0.19) and regional function (-2.2 f 1.0 vs 
-1.2 f 1.8 SD/chord, p = 0.06). 
Limitations: We attempted to define the feasibility 
of sequential lytic and mechanical reperfusion; this 
was not a randomized study. Since a placebo control 
group is absent, definitive statements concerning 
changes in ventricular function are not possible. Other 
studies,2gs30 however, have shown insignificant im- 
provement in ventricular function after conservative 
treatment. Persistent complete occlusion on initial an- 
giography may not always indicate thrombolytic fail- 
ure, as delayed lysis may occur. Whether patients 
undergoing delayed reperfusion improve ventricular 
function chronically is unknown. Because of the small 
sample size, the impact of this therapy on the mortality 
rate cannot be addressed. 
Conclusion: While intravenous SK therapy effec- 
tively induces reperfusion in many patients after AMI, 
complete occlusion or high-grade residual lesions per- 
sist in most. Addition of immediate PTCA appears to 
be an optimal treatment strategy because occluded 
vessels can be recanalized and residual obstructive 
lesions can be corrected immediately. Newer throm- 
bolytic agents, such as tissue plasminogen activator, 
may be more effective than SK in inducing reperfu- 
sion. Future randomized trials are required to deter- 
mine if immediate PTCA will show added benefits 
when these newer agents are used. However, it is clear 
that intravenous SK therapy alone does not achieve 
optimal or maximal coronary recanalization. Sequen- 
tial intravenous SK followed by immediate PTCA in 
this study achieved reperfusion with less than 70% 
residual stenosis in more than 90% of cases. Further- 
more, the reocclusion rate was only 8%. This treat- 
ment strategy therefore appears to be effective and 
overcomes some of the drawbacks of intravenous 
thrombolytic agents or PTCA alone, and should be the 
standard to which other reperfusion strategies are 
compared. 
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